CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome.
about
Exploring miRNA-Associated Signatures with Diagnostic Relevance in Glioblastoma Multiforme and Breast Cancer PatientsRole of RUNX2 in Breast CarcinogenesisCyclin D as a therapeutic target in cancerGermline mutations and polymorphisms in the origins of cancers in women.Expression of cell cycle proteins in male breast carcinoma.Systematical detection of significant genes in microarray data by incorporating gene interaction relationship in biological systems.High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers.Effects of an Indolocarbazole-Derived CDK4 Inhibitor on Breast Cancer CellsAltered PPP2R2A and Cyclin D1 expression defines a subgroup of aggressive luminal-like breast cancer.Biological effects of ray cartilage extract on human breast cancer cell line MCF-7 and its mechanism.Oncogene amplification in male breast cancer: analysis by multiplex ligation-dependent probe amplificationAn Old Story Retold: Loss of G1 Control Defines A Distinct Genomic Subtype of Esophageal Squamous Cell CarcinomaLack of association between cyclin D1 A870G (rs9344) polymorphism and esophageal squamous cell carcinoma risk: case-control study and meta-analysisGene fusions associated with recurrent amplicons represent a class of passenger aberrations in breast cancerEvaluation of CCND1 amplification and CyclinD1 expression: diffuse and strong staining of CyclinD1 could have same predictive roles as CCND1 amplification in ER positive breast cancers.An exact algorithm for finding cancer driver somatic genome alterations: the weighted mutually exclusive maximum set cover problem.Immunophenotypic and genomic characterization of papillary carcinomas of the breast.MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours.DNA amplifications in breast cancer: genotypic-phenotypic correlations.Phenotype-genotype correlation in familial breast cancer.The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications.The 11q13-q14 amplicon: clinicopathological correlations and potential drivers.Bioinformatics exploration of PAK1 (P21-activated kinase-1) revealed potential network gene elements in breast invasive carcinoma.Why (multi)targeting of cyclin-dependent kinases is a promising therapeutic option for hormone-positive breast cancer and beyond.Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K/AKT/HIF-1α/cyclin D1 pathway.Oncogenes without a Neighboring Tumor-Suppressor Gene Are More Prone to AmplificationFunctional characterization of EMSY gene amplification in human cancers.Cyclin D1 expression in Bowen's disease and cutaneous squamous cell carcinomaThe EMSY Gene Collaborates with CCND1 in Non-Small Cell Lung Carcinogenesis.Roles of human papillomavirus infection and stathmin in the pathogenesis of sinonasal inverted papilloma.Association of aberrations in one-carbon metabolism with molecular phenotype and grade of breast cancer.Downregulation of SUN2, a novel tumor suppressor, mediates miR-221/222-induced malignancy in central nervous system embryonal tumors.High-resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1.Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer.The role of CCND1 alterations during the progression of cutaneous malignant melanoma.Detection of CHK1 and CCND1 gene copy number changes in breast cancer with dual-colour fluorescence in-situ hybridization.HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.LAST, a c-Myc-inducible long noncoding RNA, cooperates with CNBP to promote CCND1 mRNA stability in human cells.microRNA Expression in Ethnic Specific Early Stage Breast Cancer: an Integration and Comparative Analysis.The effects of alternative splicing on miRNA binding sites in bladder cancer.
P2860
Q26796590-12AD5D77-E47F-4FF0-A47F-AA54FE222C82Q28084968-B674EAFE-E631-42E1-805B-3B453EB16C94Q28242623-101D7760-34C0-40D7-9A34-D058EA328D70Q33606675-46007D86-A11B-4D85-B50B-887EB31D0FAEQ33692284-B6B431F2-C545-47B9-A190-24CD4695D8EDQ33741846-66AEB1F7-AA2E-4E2D-9CEE-E282F13810D0Q33867326-797F0042-5E6D-4282-87DA-B5864D7DF2BCQ34487091-2FFE1AB1-FCBA-4A50-AA4E-5DB0566F4109Q35538100-7D6466BB-1DF7-4A17-A6B5-A1B9B6339D52Q35870797-05A17C3A-3C7A-4FB8-861D-36C0B2A71102Q36147178-27A9B7AE-5D77-45FC-8206-5EAAF394F7F7Q36177313-354AEC2C-FBA3-4F16-A7E6-89776E98DF71Q36182787-E84EFCC9-4C7B-4DAD-B390-903542D56704Q36200413-C138B49E-3C05-4F98-AEDC-C4972DC05ABAQ36595121-3D37A471-A449-4D76-BE99-93CE6BDDB282Q36865843-F2590BD1-0A9D-4EB4-81FC-4ADC97089698Q37130628-C7F258A9-4414-4B1A-9CFE-1809BB48E96BQ37174700-8DC0B401-5B4F-446A-A9CD-C4B4976687F8Q37763102-DF095318-42B2-44CE-B535-DADB6EACBE34Q37852615-8C303500-9A36-4CC0-BCD0-80047CA363CEQ37948079-6E96CBB6-E777-4ABD-8B9D-1D6FA5625953Q38066149-5F7B7E43-68CA-4995-A676-FE96FB0DC8C2Q38444442-2392FA3F-BC0E-48FC-BFE7-4970421FF1BFQ38675849-C87A3AB6-E573-4775-9F6D-F22AE41EE819Q38835733-F47B2B43-4140-402D-96A5-A3D56720B395Q39020973-AEA836A3-4793-47CF-BBD4-FDBCF2F8B514Q39511351-8E391B99-670A-45F0-ACEE-80CD951F69D9Q40514940-878B062A-CE99-4169-8F01-E1A670044CD0Q41454768-715144AA-5AEA-4726-9D62-34007CEC9377Q41738137-894F2B30-01FB-4643-B7AA-6E444A9E3C55Q42497397-5285BC02-69FE-4F74-A639-488F93C5F793Q43715641-1F01C2E1-5F20-45FC-968F-3244FCC3F478Q43856089-AF4A2777-3846-4814-A1CF-E91487C0CDB1Q43947658-CD708C93-2EB4-4936-90AF-51A7D7E67EC8Q44763194-01F0A72D-0DA5-4250-8C0E-5BD45D47486FQ45797188-67AA199E-CAA6-4A44-BCD6-7180433B41E9Q45992368-F0807417-2764-43FB-BD35-2D07A80AADCAQ47099797-B2097C5D-743E-48E3-B586-7662174BF8B5Q47142555-D8A70D52-A4E4-4541-9324-6072D0CFBC88Q47232846-C81FF0B9-FF09-4BC3-9CD2-55F0E16831E2
P2860
CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
CCND1 amplification and cyclin ...... subgroups and patient outcome.
@en
CCND1 amplification and cyclin ...... subgroups and patient outcome.
@nl
type
label
CCND1 amplification and cyclin ...... subgroups and patient outcome.
@en
CCND1 amplification and cyclin ...... subgroups and patient outcome.
@nl
prefLabel
CCND1 amplification and cyclin ...... subgroups and patient outcome.
@en
CCND1 amplification and cyclin ...... subgroups and patient outcome.
@nl
P2093
P2860
P50
P1476
CCND1 amplification and cyclin ...... subgroups and patient outcome.
@en
P2093
Claire E Paish
Maryou B K Lambros
Somaia Elsheikh
P2860
P2888
P304
P356
10.1007/S10549-007-9659-8
P407
P577
2007-07-26T00:00:00Z
P5875
P6179
1050443937